KOA Shoji HoldingsKOA SHOJI HOLDINGS CO.,LTD.9273東証プライム医薬品FY ending Jun 2026, consolidated, J-GAAP

KOA Shoji Holdings FY ending Jun 2020 results

About 64% of KOA Shoji Holdings's sales come from Drug Substance Sales Business, with Pharmaceutical Marketing Business making up much of the rest.

Out of every ¥100 of sales, about ¥14 is left as operating profit.

Where the money goes

For every ¥100 KOA Shoji Holdings sells, how much goes where, and how much is kept.

FY ending Jun 2020

Margin funnel (derived from reported values)Gross margin 29.1% → Operating margin 14.5% → Net margin 10.9%

Revenue by business segment, and the profit each one keeps.

FY ending Jun 2020

Drug Substance Sales Business¥10.3B
64%
Op. margin 18.5%Industry: Specialty Trading & Wholesale
Pharmaceutical Marketing Business¥5.72B
36%
Op. margin 7.9%Industry: Pharmaceuticals

※ Segment figures include inter-segment sales and do not sum to the company total

Show source documents (3)

EDINET (FSA Japan)
有価証券報告書－第10期(2023/07/01－2024/06/30)
ID S100UGDV2024-09-30Open
EDINET (FSA Japan)
有価証券報告書－第8期(令和3年7月1日－令和4年6月30日)
ID S100P8UB2022-09-28Open
EDINET (FSA Japan)
訂正有価証券報告書－第7期(令和2年7月1日－令和3年6月30日)
ID S100ML0J2021-10-11Open

Extracted from XBRL: 45 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.